Tag: BD1

BARD1 Life Sciences ASX BD1 world-first blood test breast cancer detection

BARD1 develops world-first blood test for breast cancer detection; offers high diagnostic accuracy

Perth-based biotech company BARD1 Life Sciences (ASX: BD1) has developed a world-first blood test for the early detection of breast cancer, claiming high diagnostic...
BARD1 Life Sciences ASX BD1 ovarian cancer test detects disease high risk women

BARD1 Life Sciences’ ovarian cancer test detects disease in high-risk women

BARD1 Life Sciences (ASX: BD1) has validated the commercial potential of its ovarian cancer screening test after new research revealed the test’s accuracy in...
BARD1 Life Sciences ASX BD1 ovarian cancer screening

BARD1 Life Sciences en route to delivering better ovarian cancer screening

BARD1 Life Sciences (ASX: BD1), a biotechnology company developing a non-invasive cancer diagnostics test for ovarian cancer, announced encouraging results today from an improved BARD1-Ovarian test...
BARD1 Life Sciences ASX BD1 ProcartaPlex technology ovarian cancer detection

BARD1 leverages ProcartaPlex technology to accelerate development of ovarian cancer detection

Australian biotech company BARD1 Life Sciences (ASX: BD1) has entered into an assay development agreement with Thermo Fisher Scientific for custom research assay development...
BARD1 Life Sciences ASX BD1 ovarian cancer test

BARD1 Life Sciences expands success in non-invasive ovarian cancer test, moves to commercialisation

BARD1 Life Sciences (ASX: BD1) has pronounced additional success for its BARD1-Ovarian test after an independent test confirmed the non-invasive diagnostic tool’s “high accuracy”...

BARD1 Life Sciences receives timely Japanese patent

Australian biotech company BARD1 Life Sciences (ASX: BD1) has been granted an important patent for cancer diagnostics in Japan. The Japan Patent Office issued Japanese...
BARD1 Life Sciences ASX BD1 ovarian cancer detection study results

BARD1 reports success in non-invasive ovarian cancer detection study

Biotech stock BARD1 Life Sciences (ASX: BD1) has achieved positive results in its non-invasive ovarian cancer diagnostic study. The OC-400 study revealed the company’s BARD1-Ovarian...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS